RPS10-NUDT3

Across TCGA pan-cancer cohorts, RPS10-NUDT3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPS10-NUDT3 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RPS10-NUDT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS10-NUDT3 expression acts as an unfavorable survival marker.

ESCA, BLCA, and PRAD are the cancer types where RPS10-NUDT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.198	0.872	.003	18	view →
BLCA	DFS	Median	All	0.159	0.625	.016	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	0.213	0.676	.012	6	view →
HNSC	OS	Median	IV	0.176	0.639	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPS10-NUDT3–ESCA (OS)

Open the ESCA breakdown →